Genomic medicine: A decade of successes, challenges, and opportunities

Science Translational Medicine

Volumn 5, Issue 189, 2013, Pages

  McCarthy, Jeanette J ^a,b   McLeod, Howard L ^c   Ginsburg, Geoffrey S ^a  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CARBAMAZEPINE; CLOPIDOGREL; CRIZOTINIB; ERLOTINIB; EVEROLIMUS; GEFITINIB; MERCAPTOPURINE; TRASTUZUMAB; TUMOR MARKER; VEMURAFENIB; WARFARIN;

BLADDER CANCER; BREAST CANCER; CLINICAL PRACTICE; DIAGNOSTIC TEST; DRUG EFFICACY; EDUCATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC DISORDER; GENOMIC MEDICINE; GENOMICS; HAIRY CELL LEUKEMIA; HEPATITIS C; HUMAN; HUMAN GENOME; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEGAL ASPECT; LUNG NON SMALL CELL CANCER; MEDICINE; MELANOMA; MICROORGANISM; NEWBORN SCREENING; NEXT GENERATION SEQUENCING; PHARMACOGENOMICS; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROGNOSIS; REIMBURSEMENT; REVIEW; RISK ASSESSMENT;

GENOMICS; HUMANS; NEOPLASMS; PHARMACOGENETICS;

EID: 84880557325     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3005785     Document Type: Review

References (169)

1. B. B. Spear, M. Heath-Chiozzi, J. Huff, Clinical application of pharmacogenetics. Trends Mol. Med. 7, 201-204 (2001).
2. R. J. Klein, C. Zeiss, E. Y. Chew, J. Y. Tsai, R. S. Sackler, C. Haynes, A. K. Henning, J. P. SanGiovanni, S. M. Mane, S. T. Mayne, M. B. Bracken, F. L. Ferris, J. Ott, C. Barnstable, J. Hoh, Complement factor H polymorphism in age-related macular degeneration. Science 308, 385-389 (2005).
3. K. A. Wetterstrand, DNA sequencing costs: Data from the NHGRI Genome Sequencing Program (GSP); http://www.genome.gov/sequencingcosts.
4. E. S. Lander, Initial impact of the sequencing of the human genome. Nature 470, 187-197 (2011).
5. S. D. Boyd, Diagnostic applications of high-throughput DNA sequencing. Annu. Rev. Pathol. 8, 381-410 (2013).
6. 1000 Genomes Project Consortium, G. R. Abecasis, A. Auton, L. D. Brooks, M. A. DePristo, R. M. Durbin, R. E. Handsaker, H. M. Kang, G. T. Marth, G. A. McVean, An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56-65 (2012).
7. M. B. Gerstein, A. Kundaje, M. Hariharan, S. G. Landt, K. K. Yan, C. Cheng, X. J. Mu, E. Khurana, J. Rozowsky, R. Alexander, R.Min, P. Alves, A. Abyzov, N. Addleman, N. Bhardwaj, A. P. Boyle, P. Cayting, A. Charos, D. Z. Chen, Y. Cheng, D. Clarke, C. Eastman, G. Euskirchen, S. Frietze, Y. Fu, J. Gertz, F. Grubert, A. Harmanci, P. Jain, M. Kasowski, P. Lacroute, J. Leng, J. Lian, H. Monahan, H. O'Geen, Z. Ouyang, E. C. Partridge, D. Patacsil, F. Pauli, D. Raha, L. Ramirez, T. E. Reddy, B. Reed, M. Shi, T. Slifer, J. Wang, L. Wu, X. Yang, K. Y. Yip, G. Zilberman-Schapira, S. Batzoglou, A. Sidow, P. J. Farnham, R. M. Myers, S. M. Weissman, M. Snyder, Architecture of the human regulatory network derived from ENCODE data. Nature 489, 91-100 (2012).
8. S. B. Ng, E. H. Turner, P. D. Robertson, S. D. Flygare, A. W. Bigham, C. Lee, T. Shaffer, M. Wong, A. Bhattacharjee, E. E. Eichler, M. Bamshad, D. A. Nickerson, J. Shendure, Targeted capture and massively parallel sequencing of 12 human exomes. Nature 461, 272-276 (2009).
9. S. B. Ng, K. J. Buckingham, C. Lee, A. W. Bigham, H. K. Tabor, K.M. Dent, C. D. Huff, P. T. Shannon, E. W. Jabs, D. A. Nickerson, J. Shendure, M. J. Bamshad, Exome sequencing identifies the cause of a mendelian disorder. Nat. Genet. 42, 30-35 (2010).
10. M. Choi, U. I. Scholl, W. Ji, T. Liu, I. R. Tikhonova, P. Zumbo, A. Nayir, A. Bakkaloǧlu, S. Ozen, S. Sanjad, C. Nelson-Williams, A. Farhi, S. Mane, R. P. Lifton, Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc. Natl. Acad. Sci. U.S.A. 106, 19096-19101 (2009).
11. B. Rabbani, N. Mahdieh, K. Hosomichi, H. Nakaoka, I. Inoue, Next-generation sequencing: Impact of exome sequencing in characterizing Mendelian disorders. J. Hum. Genet. 57, 621-632 (2012).
12. F. S. Ong, K. Das, J. Wang, H. Vakil, J. Z. Kuo, W. L. Blackwell, S. W. Lim, M. O. Goodarzi, K. E. Bernstein, J. I. Rotter, W. W. Grody, Personalized medicine and pharmacogenetic biomarkers: Progress in molecular oncology testing. Expert Rev. Mol. Diagn. 12, 593-602 (2012).
13. S. R. Harris, E. J. Cartwright, M. E. Török, M. T. Holden, N. M. Brown, A. L. Ogilvy-Stuart, M. J. Ellington, M. A. Quail, S. D. Bentley, J. Parkhill, S. J. Peacock, Whole-genome sequencing for analysis of an outbreak of meticillin-resistant Staphylococcus aureus: A descriptive study. Lancet Infect. Dis. 13, 130-136 (2013).
14. P. Sanseau, P. Agarwal, M. R. Barnes, T. Pastinen, J. B. Richards, L. R. Cardon, V. Mooser, Use of genome-wide association studies for drug repositioning. Nat. Biotechnol. 30, 317-320 (2012).
15. M. Sirota, J. T. Dudley, J. Kim, A. P. Chiang, A. A. Morgan, A. Sweet-Cordero, J. Sage, A. J. Butte, Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3, 96ra77 (2011).
16. J. T. Dudley, M. Sirota,M. Shenoy, R. K. Pai, S. Roedder, A. P. Chiang, A. A.Morgan, M. M. Sarwal, P. J. Pasricha, A. J. Butte, Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci. Transl. Med. 3, 96ra76 (2011).
17. D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, W. L. McGuire, Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987).
18. D. J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga, L. Norton, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
19. S. J. Schnitt, T. W. Jacobs, Current status of HER2 testing: Caught between a rock and a hard place. Am. J. Clin. Pathol. 116, 806-810 (2001).
20. M. E. Hammond, P. L. Fitzgibbons, C. C. Compton, D. J. Grignon, D. L. Page, L. P. Fielding, D. Bostwick, T. F. Pajak, College of American Pathologists Conference XXXV: Solid tumor prognostic factors - Which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants. Arch. Pathol. Lab. Med. 124, 958-965 (2000).
21. V. Pawlowski, F. Révillion, L. Hornez, J. P. Peyrat, A real-time one-step reverse transcriptasepolymerase chain reaction method to quantify c-erbB-2 expression in human breast cancer. Cancer Detect. Prev. 24, 212-223 (2000).
22. J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, G. N. Hortobagyi, The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14, 320-368 (2009).
23. T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. Brannigan, P. L. Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, D. N. Louis, D. C. Christiani, J. Settleman, D. A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
24. J. G. Paez, P. A. Jänne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F. J. Kaye, N. Lindeman, T. J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. J. Eck, W. R. Sellers, B. E. Johnson, M. Meyerson, EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
25. C. J. Allegra, J. M. Jessup, M. R. Somerfield, S. R. Hamilton, E. H. Hammond, D. F. Hayes, P. K. McAllister, R. F. Morton, R. L. Schilsky, American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27, 2091-2096 (2009).
26. U.S. Food and Drug Administration, Cetuximab in combination with Folfiri/Therascreen; http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ ucm310933.htm.
27. U.S. Food and Drug Administration, Drug approval package: Xalkori capsules; http:// www.accessdata.fda.gov/drugsatfda-docs/nda/2011/ 202570Orig1s000TOC.cfm.
28. U.S. Food and Drug Administration, Drug approval package: Zelboraf (vemurafenib) tablet; http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/ 202429s000TOC.cfm.
29. M. Röring, T. Brummer, Aberrant B-Raf signaling in human cancer - 10 years from bench to bedside. Crit. Rev. Oncog. 17, 97-121 (2012).
30. E. Tiacci, V. Trifonov, G. Schiavoni, A. Holmes, W. Kern, M. P. Martelli, A. Pucciarini, B. Bigerna, R. Pacini, V. A. Wells, P. Sportoletti, V. Pettirossi, R. Mannucci, O. Elliott, A. Liso, A. Ambrosetti, A. Pulsoni, F. Forconi, L. Trentin, G. Semenzato, G. Inghirami, M. Capponi, F. Di Raimondo, C. Patti, L. Arcaini, P. Musto, S. Pileri, C. Haferlach, S. Schnittger, G. Pizzolo, R. Foà, L. Farinelli, T. Haferlach, L. Pasqualucci, R. Rabadan, B. Falini, BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364, 2305-2315 (2011).
31. S. Dietrich, H. Glimm, M. Andrulis, C. von Kalle, A. D. Ho, T. Zenz, BRAF inhibition in refractory hairy-cell leukemia. N. Engl. J. Med. 366, 2038-2040 (2012).
32. Y. P. Mosse, F. M. Balis, M. S. Lim, J. Laliberte, S. D. Voss, E. Fox, R. Bagatell, B. Weigel, P. C. Adamson, A. M Ingle, C. H. Ahern, S. Blaney, Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study. J. Clin. Oncol. 30, abstr. 9500 (2012).
33. G. Iyer, A. J. Hanrahan, M. I. Milowsky, H. Al-Ahmadie, S. N. Scott, M. Janakiraman, M. Pirun, C. Sander, N. D. Socci, I. Ostrovnaya, A. Viale, A. Heguy, L. Peng, T. A. Chan, B. Bochner, D. F. Bajorin, M. F. Berger, B. S. Taylor, D. B. Solit, Genome sequencing identifies a basis for everolimus sensitivity. Science 338, 221 (2012).
34. R. Katayama, A. T. Shaw, T. M. Khan,M. Mino-Kenudson, B. J. Solomon, B. Halmos, N. A. Jessop, J. C.Wain, A. T. Yeo, C. Benes, L.Drew, J. C. Saeh, K. Crosby, L. V. Sequist, A. J. Iafrate, J. A. Engelman, Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 4, 120ra17 (2012).
35. H. L. McLeod, Cancer pharmacogenomics: Early promise, but concerted effort needed. Science 339, 1563-1566 (2013).
36. R. J. Leary, I. Kinde, F.Diehl, K. Schmidt, C. Clouser, C. Duncan, A. Antipova, C. Lee, K. McKernan, F. M. De La Vega, K. W. Kinzler, B. Vogelstein, L. A. Diaz Jr., V. E. Velculescu, Development of personalized tumor biomarkers using massively parallel sequencing. Sci. Transl. Med. 2, 20ra14 (2010).
37. R. J. Leary, M. Sausen, I. Kinde, N. Papadopoulos, J. D. Carpten, D. Craig, J. O'Shaughnessy, K. W. Kinzler, G. Parmigiani, B. Vogelstein, L. A. Diaz Jr., V. E. Velculescu, Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci. Transl. Med. 4, 162ra154 (2012).
38. S. J. Dawson, D. W. Tsui, M. Murtaza, H. Biggs, O. M. Rueda, S. F. Chin, M. J. Dunning, D. Gale, T. Forshew, B. Mahler-Araujo, S. Rajan, S. Humphray, J. Becq, D. Halsall, M. Wallis, D. Bentley, C. Caldas, N. Rosenfeld, Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199-1209 (2013).
39. M. J. Bamshad, J. A. Shendure, D. Valle, A. Hamosh, J. R. Lupski, R. A. Gibbs, E. Boerwinkle, R. P. Lifton, M. Gerstein, M. Gunel, S. Mane, D. A. Nickerson; Centers for Mendelian Genomics, The Centers for Mendelian Genomics: A new large-scale initiative to identify the genes underlying rare Mendelian conditions. Am. J. Med. Genet. A 158A, 1523-1525 (2012).
40. E. A. Worthey, A. N. Mayer, G. D. Syverson, D. Helbling, B. B. Bonacci, B. Decker, J. M. Serpe, T. Dasu, M. R. Tschannen, R. L. Veith, M. J. Basehore, U. Broeckel, A. Tomita-Mitchell, M. J. Arca, J. T. Casper, D. A. Margolis, D. P. Bick, M. J. Hessner, J. M. Routes, J. W. Verbsky, H. J. Jacob, D. P. Dimmock, Making a definitive diagnosis: Successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet. Med. 13, 255-262 (2011).
41. A. C. Need, V. Shashi, Y. Hitomi, K. Schoch, K. V. Shianna, M. T.McDonald, M. H. Meisler, D. B. Goldstein, Clinical application of exome sequencing in undiagnosed genetic conditions. J. Med. Genet. 49, 353-361 (2012).
42. C. Gilissen, A. Hoischen, H. G. Brunner, J. A. Veltman, Disease gene identification strategies for exome sequencing. Eur. J. Hum. Genet. 20, 490-497 (2012).
43. Secretary's Advisory Committee on Heritable Disorders in Newborns and Children, Newborn screening: Towards a uniform screening panel and system; http://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/ uniformscreening.pdf.
44. A. J. Goldenberg, R. R. Sharp, The ethical hazards and programmatic challenges of genomic newborn screening. JAMA 307, 461-462 (2012).
45. Y. M. Lo, N. Corbetta, P. F. Chamberlain, V. Rai, I. L. Sargent, C. W. Redman, J. S. Wainscoat, Presence of fetal DNA in maternal plasma and serum. Lancet 350, 485-487 (1997).
46. H. C. Fan, Y. J. Blumenfeld, U. Chitkara, L. Hudgins, S. R. Quake, Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc. Natl. Acad. Sci. U.S.A. 105, 16266-16271 (2008).
47. R. W. Chiu, K. C. Chan, Y. Gao, V. Y. Lau, W. Zheng, T. Y. Leung, C. H. Foo, B. Xie, N. B. Tsui, F. M. Lun, B. C. Zee, T. K. Lau, C. R. Cantor, Y. M. Lo, Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc. Natl. Acad. Sci. U.S.A. 105, 20458-20463 (2008).
48. D. W. Bianchi, From prenatal genomic diagnosis to fetal personalized medicine: Progress and challenges. Nat. Med. 18, 1041-1051 (2012).
49. Sequenom Inc., Sequenom, Inc. reports financial results for the third quarter of 2012 and announces 90,000 annualized run rate for Maternit21 PLUS tests; http://sequenom.investorroom.com/2012-11-08-Sequenom-Inc.-Reports- Financial-Results-For-The-Third-Quarter-Of-2012- And-Announces-90-000- Annualized-Run-Rate-For-MaterniT21-PLUS-Tests.
50. Y. M. Lo, K. C. Chan, H. Sun, E. Z. Chen, P. Jiang, F. M. Lun, Y. W. Zheng, T. Y. Leung, T. K. Lau, C. R. Cantor, R. W. Chiu, Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci. Transl. Med. 2, 61ra91 (2010).
51. J. O. Kitzman, M. W. Snyder, M. Ventura, A. P. Lewis, R. Qiu, L. E. Simmons, H. S. Gammill, C. E. Rubens, D. A. Santillan, J. C. Murray, H. K. Tabor, M. J. Bamshad, E. E. Eichler, J. Shendure, Noninvasive whole-genome sequencing of a human fetus. Sci. Transl. Med. 4, 137ra76 (2012).
52. H. C. Fan, W. Gu, J. Wang, Y. J. Blumenfeld, Y. Y. El-Sayed, S. R. Quake, Non-invasive prenatal measurement of the fetal genome. Nature 487, 320-324 (2012).
53. H. C. Fan, W. Gu, J. Wang, Y. J. Blumenfeld, Y. Y. El-Sayed, S. R. Quake, Erratum: Noninvasive prenatal measurement of the fetal genome. Nature 489, 326 (2012).
54. McKusick-Nathans Institute of Genetic Medicine, Online Mendelian Inheritance in Man, OMIM; http://omim.org/ [accessed 28 December 2012].
55. M. M. Kaback, Population-based genetic screening for reproductive counseling: The Tay-Sachs disease model. Eur. J. Pediatr. 159 (Suppl. 3), S192-S195 (2000).
56. C. J. Bell, D. L. Dinwiddie, N. A. Miller, S. L. Hateley, E. E. Ganusova, J. Mudge, R. J. Langley, L. Zhang, C. C. Lee, F. D. Schilkey, V. Sheth, J. E. Woodward, H. E. Peckham, G. P. Schroth, R. W. Kim, S. F. Kingsmore, Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci. Transl. Med. 3, 65ra4 (2011).
57. C. S. Ku, E. K. Tan, D. N. Cooper, From the periphery to centre stage: De novo single nucleotide variants play a key role in human genetic disease. J. Med. Genet. 50, 203-211 (2013).
58. A. Kiezun, K. Garimella, R. Do, N. O. Stitziel, B. M. Neale, P. J. McLaren, N. Gupta, P. Sklar, P. F. Sullivan, J. L. Moran, C. M. Hultman, P. Lichtenstein, P. Magnusson, T. Lehner, Y. Y. Shugart, A. L. Price, P. I. de Bakker, S. M. Purcell, S. R. Sunyaev, Exome sequencing and the genetic basis of complex traits. Nat. Genet. 44, 623-630 (2012).
59. M. J. Emond, T. Louie, J. Emerson, W. Zhao, R. A. Mathias, M. R. Knowles, F. A. Wright, M. J. Rieder, H. K. Tabor, D. A. Nickerson, K. C. Barnes; National Heart, Lung, and Blood Institute (NHLBI) GO Exome Sequencing Project; G. O. Lung, R. L. Gibson, M. J. Bamshad, Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nat. Genet. 44, 886-889 (2012).
60. D. H. Roukos, E. Briasoulis, Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nat. Clin. Pract. Oncol. 4, 578-590 (2007).
61. U. Ladabaum, G. Wang, J. Terdiman, A. Blanco, M. Kuppermann, C. R. Boland, J. Ford, E. Elkin, K. A. Phillips, Strategies to identify the Lynch syndrome among patients with colorectal cancer: A cost-effectiveness analysis. Ann. Intern. Med. 155, 69-79 (2011).
62. M. Chang, P. H. Green, Genetic testing before serologic screening in relatives of patients with celiac disease as a cost containment method. J. Clin. Gastroenterol. 43, 43-50 (2009).
63. C. B. Do, D. A. Hinds, U. Francke, N. Eriksson, Comparison of family history and SNPs for predicting risk of complex disease. PLoS Genet. 8, e1002973 (2012).
64. S. Mallal, E. Phillips, G. Carosi, J. M. Molina, C. Workman, J. Tomazic, E. Jägel-Guedes, S. Rugina, O. Kozyrev, J. F. Cid, P. Hay, D. Nolan, S. Hughes, A. Hughes, S. Ryan, N. Fitch, D. Thorborn, A. Benbow; PREDICT-1 Study Team, HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-579 (2008).
65. W. H. Chung, S. I. Hung, H. S. Hong, M. S. Hsih, L. C. Yang, H. C. Ho, J. Y. Wu, Y. T. Chen, Medical genetics: A marker for Stevens-Johnson syndrome. Nature 428, 486 (2004).
66. C. J. Ross, H. Katzov-Eckert, M. P. Dubé, B. Brooks, S. R. Rassekh, A. Barhdadi, Y. Feroz-Zada, H. Visscher, A. M. Brown, M. J. Rieder, P. C. Rogers, M. S. Phillips, B. C. Carleton, M. R. Hayden; CPNDS Consortium, Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet. 41, 1345-1349 (2009).
67. S. Rost, A. Fregin, V. Ivaskevicius, E. Conzelmann, K. Hörtnagel, H. J. Pelz, K. Lappegard, E. Seifried, I. Scharrer, E. G. Tuddenham, C. R. Müller, T. M. Strom, J. Oldenburg, Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427, 537-541 (2004).
68. G. P. Aithal, C. P. Day, P. J. Kesteven, A. K. Daly, Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717-719 (1999).
69. M. V. Holmes, P. Perel, T. Shah, A. D. Hingorani, J. P. Casas, CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: A systematic review and metaanalysis. JAMA 306, 2704-2714 (2011).
70. D. R. Booth, G. Ahlenstiel, J. George, Pharmacogenomics of hepatitis C infections: Personalizing therapy. Genome Med. 4, 99 (2012).
71. Z. Zhang, An in vitro diagnostic multivariate index assay (IVDMIA) for ovarian cancer: Harvesting the power of multiple biomarkers. Rev. Obstet. Gynecol. 5, 35-41 (2012).
72. M. Dowsett, J. Cuzick, C. Wale, J. Forbes, E. A. Mallon, J. Salter, E. Quinn, A. Dunbier, M. Baum, A. Buzdar, A. Howell, R. Bugarini, F. L. Baehner, S. Shak, Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J. Clin. Oncol. 28, 1829-1834 (2010).
73. K. S. Albain, W. E. Barlow, S. Shak, G. N. Hortobagyi, R. B. Livingston, I. T. Yeh, P. Ravdin, R. Bugarini, F. L. Baehner, N. E. Davidson, G.W. Sledge, E. P. Winer, C. Hudis, J. N. Ingle, E. A. Perez, K. I. Pritchard, L. Shepherd, J. R. Gralow, C. Yoshizawa, D. C. Allred, C. K. Osborne, D. F. Hayes; Breast Cancer Intergroup of North America, Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogenreceptor- positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol. 11, 55-65 (2010).
74. S. Paik, G. Tang, S. Shak, C. Kim, J. Baker, W. Kim, M. Cronin, F. L. Baehner, D. Watson, J. Bryant, J. P. Costantino, C. E. Geyer Jr., D. L. Wickerham, N. Wolmark, Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 3726-3734 (2006).
75. S. Paik, S. Shak, G. Tang, C. Kim, J. Baker, M. Cronin, F. L. Baehner, M. G. Walker, D. Watson, T. Park, W. Hiller, E. R. Fisher, D. L. Wickerham, J. Bryant, N. Wolmark, A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004).
76. U.S. Food and Drug Administration, Draft guidance for industry, clinical laboratories, and FDA staff: In vitro diagnostic multivariate index assays; http://www.fda.gov/downloads/MedicalDevices/.../ucm071455.pdf.
77. H. A. AzimJr., S. Michiels, F. Zagouri, S. Delaloge, M. Filipits, M. Namer, P. Neven,W. F. Symmans, A. Thompson, F. André, S. Loi, C. Swanton, Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Ann. Oncol. 24, 647-654 (2013).
78. S. Rosenberg, M. R. Elashoff, P. Beineke, S. E. Daniels, J. A. Wingrove, W. G. Tingley, P. T. Sager, A. J. Sehnert, M. Yau, W. E. Kraus, L. K. Newby, R. S. Schwartz, S. Voros, S. G. Ellis, N. Tahirkheli, R. Waksman, J. McPherson, A. Lansky, M. E. Winn, N. J. Schork, E. J. Topol; PREDICT (Personalized Risk Evaluation and Diagnosis in the Coronary Tree) Investigators, Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann. Intern. Med. 153, 425-434 (2010).
79. U.S. Centers for Medicare and Medicaid Services, New and reconsidered clinical laboratory fee schedule; http://www.cms.gov/Medicare/Medicare-Fee-for- Service-Payment/ClinicalLabFeeSched/Downloads/CLFS-CY2013-Preliminary-Payment- Determinations.pdf.
80. G. M. Weinstock, Genomic approaches to studying the human microbiota. Nature 489, 250-256 (2012).
81. D. A. Relman, Microbial genomics and infectious diseases. N. Engl. J. Med. 365, 347-357 (2011).
82. Human Microbiome Project Consortium, Structure, function and diversity of the healthy human microbiome. Nature 486, 207-214 (2012).
83. J. Qin, Y. Li, Z. Cai, S. Li, J. Zhu, F. Zhang, S. Liang, W. Zhang, Y. Guan, D. Shen, Y. Peng, D. Zhang, Z. Jie, W. Wu, Y. Qin, W. Xue, J. Li, L. Han, D. Lu, P. Wu, Y. Dai, X. Sun, Z. Li, A. Tang, S. Zhong, X. Li, W. Chen, R. Xu, M. Wang, Q. Feng, M. Gong, J. Yu, Y. Zhang, M. Zhang, T. Hansen, G. Sanchez, J. Raes, G. Falony, S. Okuda, M. Almeida, E. LeChatelier, P. Renault, N. Pons, J. M. Batto, Z. Zhang, H. Chen, R. Yang, W. Zheng, S. Li, H. Yang, J. Wang, S. D. Ehrlich, R. Nielsen, O. Pedersen, K. Kristiansen, J. Wang, A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55-60 (2012).
84. I. Cho, M. J. Blaser, The human microbiome: At the interface of health and disease. Nat. Rev. Genet. 13, 260-270 (2012).
85. K. J. Maloy, F. Powrie, Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474, 298-306 (2011).
86. I. Mukhopadhya, R. Hansen, E. M. El-Omar, G. L. Hold, IBD - What role do Proteobacteria play? Nat. Rev. Gastroenterol. Hepatol. 9, 219-230 (2012).
87. T. J. Borody, A. Khoruts, Fecal microbiota transplantation and emerging applications. Nat. Rev. Gastroenterol. Hepatol. 9, 88-96 (2011).
88. M. A. Marra, S. J. Jones, C. R. Astell, R. A. Holt, A. Brooks-Wilson, Y. S. Butterfield, J. Khattra, J. K. Asano, S. A. Barber, S. Y. Chan, A. Cloutier, S. M. Coughlin, D. Freeman, N. Girn, O. L. Griffith, S. R. Leach, M. Mayo, H. McDonald, S. B. Montgomery, P. K. Pandoh, A. S. Petrescu, A. G. Robertson, J. E. Schein, A. Siddiqui, D. E. Smailus, J. M. Stott, G. S. Yang, F. Plummer, A. Andonov, H. Artsob, N. Bastien, K. Bernard, T. F. Booth, D. Bowness, M. Czub, M. Drebot, L. Fernando, R. Flick, M. Garbutt, M. Gray, A. Grolla, S. Jones, H. Feldmann, A. Meyers, A. Kabani, Y. Li, S. Normand, U. Stroher, G. A. Tipples, S. Tyler, R. Vogrig, D. Ward, B. Watson, R. C. Brunham, M. Krajden, M. Petric, D. M. Skowronski, C. Upton, R. L. Roper, The genome sequence of the SARS-associated coronavirus. Science 300, 1399-1404 (2003).
89. C. S. Chin, J. Sorenson, J. B. Harris, W. P. Robins, R. C. Charles, R. R. Jean-Charles, J. Bullard, D. R. Webster, A. Kasarskis, P. Peluso, E. E. Paxinos, Y. Yamaichi, S. B. Calderwood, J. J. Mekalanos, E. E. Schadt, M. K. Waldor, The origin of the Haitian cholera outbreak strain. N. Engl. J. Med. 364, 33-42 (2011).
90. J. L. Gardy, J. C. Johnston, S. J. Ho Sui, V. J. Cook, L. Shah, E. Brodkin, S. Rempel, R. Moore, Y. Zhao, R. Holt, R. Varhol, I. Birol, M. Lem, M. K. Sharma, K. Elwood, S. J. Jones, F. S. Brinkman, R. C. Brunham, P. Tang, Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. N. Engl. J. Med. 364, 730-739 (2011).
91. G. J. Smith, D. Vijaykrishna, J. Bahl, S. J. Lycett, M.Worobey, O. G. Pybus, S. K. Ma, C. L. Cheung, J. Raghwani, S. Bhatt, J. S. Peiris, Y. Guan, A. Rambaut, Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 459, 1122-1125 (2009).
92. E. S. Snitkin, A. M. Zelazny, P. J. Thomas, F. Stock; NISC Comparative Sequencing Program Group, D. K. Henderson, T. N. Palmore, J.A. Segre, Tracking a hospital outbreak of carbapenemresistant Klebsiella pneumoniae with whole-genome sequencing. Sci. Transl. Med. 4, 148ra116 (2012).
93. E. D. Green, M. S. Guyer; National Human Genome Research Institute, Charting a course for genomic medicine from base pairs to bedside. Nature 470, 204-213 (2011).
94. J. E. Haddow, G. E. Palomaki, in Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease, M. Khoury, J. Little, W. Burke, Eds. (Oxford Univ. Press, New York, 2003), pp. 217-233.
95. S. R. Tunis, D. B. Stryer, C. M. Clancy, Practical clinical trials: Increasing the value of clinical research for decision making in clinical and health policy. JAMA 290, 1624-1632 (2003).
96. D. A. Mrazek, C. Lerman, Facilitating clinical implementation of pharmacogenomics. JAMA 306, 304-305 (2011).
97. G. S. Ginsburg, J. Staples, A. P. Abernethy, Academic medical centers: Ripe for rapidlearning personalized health care. Sci. Transl. Med. 3, 101cm27 (2011).
98. G. S. Ginsburg, N. M. Kuderer, Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: A common bond. J. Clin. Oncol. 30, 4233-4242 (2012).
99. M. W. Foster, J. J. Mulvihill, R. R. Sharp, Evaluating the utility of personal genomic information. Genet. Med. 11, 570-574 (2009).
100. S. D. Grosse, C. M. McBride, J. P. Evans, M. J. Khoury, Personal utility and genomic information: Look before you leap. Genet. Med. 11, 575-576 (2009).
101. J. R. Botkin, S.M. Teutsch, C. I. Kaye, M. Hayes, J. E. Haddow, L. A. Bradley, K. Szegda,W. D. Dotson; EGAPP Working Group, Outcomes of interest in evidence-based evaluations of genetic tests. Genet. Med. 12, 228-235 (2010).
102. M. J. Khoury, C. M. McBride, S. D. Schully, J. P. Ioannidis, W. G. Feero, A. C. Janssens, M. Gwinn, D. G. Simons-Morton, J. M. Bernhardt, M. Cargill, S. J. Chanock, G. M. Church, R. J. Coates, F. S. Collins, R. T. Croyle, B. R. Davis, G. J. Downing, A. Duross, S. Friedman, M. H. Gail, G. S. Ginsburg, R. C. Green, M. H. Greene, P. Greenland, J. R. Gulcher, A. Hsu, K. L. Hudson, S. L. Kardia, P. L. Kimmel, M. S. Lauer, A. M. Miller, K. Offit, D. F. Ransohoff, J. S. Roberts, R. S. Rasooly, K. Stefansson, S. F. Terry, S. M. Teutsch, A. Trepanier, K. L. Wanke, J. S. Witte, J. Xu; Centers for Disease Control and Prevention, The Scientific Foundation for personal genomics: Recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet. Med. 11, 559-567 (2009).
103. U.S. Food and Drug Administration, Table of pharmacogenomic biomarkers in drug labels; http://www.fda.gov/drugs/scienceresearch/researchareas/ pharmacogenetics/ucm083378.htm.
104. C. F. Thorn, T. E. Klein, R. B. Altman, Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics 11, 501-505 (2010).
105. W. S. Rubinstein, D. R. Maglott, J. M. Lee, B. L. Kattman, A. J. Malheiro, M. Ovetsky, V. Hem, V. Gorelenkov, G. Song, C. Wallin, N. Husain, S. Chitipiralla, K. S. Katz, D. Hoffman, W. Jang, M. Johnson, F. Karmanov, A. Ukrainchik, M. Denisenko, C. Fomous, K. Hudson, J. M. Ostell, The NIH genetic testing registry: A new, centralized database of genetic tests to enable access to comprehensive information and improve transparency. Nucleic Acids Res. 41, D925-D935 (2013).
106. U.S. Centers for Medicare and Medicaid Services, Update on horizon scans of genetic tests currently available for clinical use in cancers; http://www.cms.gov/Medicare/Coverage/ DeterminationProcess/downloads/id81TA.pdf.
107. U.S. Centers for Medicare and Medicaid Services, Update on mapping the landscape of genetic tests for non-cancer diseases/conditions; http://www.cms.gov/Medicare/Coverage/ DeterminationProcess/downloads/id86TA.pdf.
108. A. O. Berg, The CDC's EGAPP initiative: Evaluating the clinical evidence for genetic tests. Am. Fam. Physician 80, 1218 (2009).
109. M. V. Relling, T. E. Klein, CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89, 464-467 (2011).
110. M. S. Williams, in Genomic and Personalized Medicine, G. Ginsburg, H. Willard, Eds. (Elsevier, New York, ed. 2, 2013), vol. 1, pp. 340-352.
111. J. E. Dancey, P. L. Bedard, N. Onetto, T. J. Hudson, The genetic basis for cancer treatment decisions. Cell 148, 409-420 (2012).
112. L. Goetz, K. Bethel, E. J. Topol, Rebooting cancer tissue handling in the sequencing era: Toward routine use of frozen tumor tissue. JAMA 309, 37-38 (2013).
113. G. Gerhard, D. J. Carey, G. D. Steele, in Genomic and Personalized Medicine, G. Ginsburg, H. Willard, Eds. (Elsevier, New York, ed. 2, 2013), vol. 1, pp. 287-294.
114. K. Kawamoto, D. F. Lobach, H. F. Willard, G. S. Ginsburg, A national clinical decision support infrastructure to enable the widespread and consistent practice of genomic and personalized medicine. BMC Med. Inform. Decis. Mak. 9, 17 (2009).
115. J. Starren, M. S. Williams, E. P. Bottinger, Crossing the omic chasm: A time for omic ancillary systems. JAMA 309, 1237-1238 (2013).
116. Health Level 7, Implementation guide for CDA release 2 genetic testing report (GTR); http://www.hl7.org/documentcenter/public-temp-965C9715-1C23-BA17- 0C02E787ABE1A9D8/ wg/clingenomics/docs/GeneticTesting Report (GTR) - 2012.10.30.pdf.
117. J. Woodcock, in Genomic and Personalized Medicine, G. Ginsburg, H. Willard, Eds. (Elsevier, New York, ed. 2, 2013), pp. 422-432.
118. U.S. Food and Drug Administration, Class II special controls guidance document: Drug metabolizing enzyme genotyping system - Guidance for industry and FDA staff; http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ GuidanceDocuments/ucm077933.htm.
119. U.S. Food and Drug Administration, Guidance for industry and Food and Drug Administration staff - Factors to consider when making benefit-risk determinations in medical device premarket approvals and de novo classifications; http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ GuidanceDocuments/ucm267829.htm.
120. U.S. National Institutes of Health, Direct-to-consumer genetic testing: Report of the Secretary's Advisory Committee on Genetics, Health, and Society; http://oba.od.nih.gov/oba/ sacghs/reports/SACGHS-DTC-Report-2010.pdf.
121. U.S. National Institutes of Health, U.S. system of oversight of genetic testing: A response to the charge of the Secretary of Health and Human Services; http://oba.od.nih.gov/oba/ SACGHS/reports/SACGHS-oversight-report.pdf.
122. U.S. Food and Drug Administration, Oversight of laboratory developed tests; Public meeting; Request for comments; http://www.gpo.gov/fdsys/pkg/FR- 2010-06-17/html/ 2010-14654.htm.
123. A. Hresko, S. B. Haga, Insurance coverage policies for personalized medicine. J. Pers. Med. 2, 201-216 (2012).
124. U.S. Centers for Medicare and Medicaid Services, MEDCAC Meeting 2/25/2009 - Genetic (genomic) testing; http://www.cms.gov/medicare-coverage-database/ details/medcacmeeting-details.aspx?MEDCACId=47&NCAId=224&ver= 15&NcaName=Pharmacogenomic+ Testing+for+Warfarin+Response&bc= ACAAAAAAEAAA&.
125. New and reconsidered clinical laboratory fee schedule test codes and preliminary payment determinations; http://www.cms.gov/Center/Provider-Type/ Clinical-Labs-Center.html.
126. R. Cook-Deegan, Patent law. Law and science collide over human gene patents. Science 338, 745-747 (2012).
127. M. Gymrek, A. L. McGuire, D. Golan, E. Halperin, Y. Erlich, Identifying personal genomes by surname inference. Science 339, 321-324 (2013).
128. J. Kaye, P. Boddington, J. de Vries, N. Hawkins, K. Melham, Ethical implications of the use of whole genome methods in medical research. Eur. J. Hum. Genet. 18, 398-403 (2010).
129. J. S. King, Genetic tests: Politics and fetal diagnostics collide. Nature 491, 33-34 (2012).
130. S. B. Haga, in Genomic and Personalized Medicine, G. Ginsburg, H. Willard, Eds. (Elsevier, New York, ed. 2, 2013), vol. 1, pp. 392-404.
131. American College of Medical Genetics, Points to consider in the clinical application of genomic sequencing; http://www.acmg.net/StaticContent/PPG/ Clinical-Application-of-Genomic-Sequencing.pdf.
132. American College of Medical Genetics, ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing; http://www.acmg.net/docs/ACMG- Releases-Highly-Anticipated-Recommendations-on- Incidental-Findings-in-Clinical- Exome-and-Genome-Sequencing.pdf.
133. American College of Medical Genetics, Incidental findings in clinical genomics: A clarification; http://www.acmg.net/docs/Incidental-Findings-in- Clinical-Genomics-A-Clarification.pdf.
134. U.S. National Human Genome Research Institute, Characterizing and displaying genetic variants for clinical action workshop; http://www.genome.gov/ 27546546.
135. R. A. Schnoll, A. E. Shields, Physician barriers to incorporating pharmacogenetic treatment strategies for nicotine dependence into clinical practice. Clin. Pharmacol. Ther. 89, 345-347 (2011).
136. S. B. Haga, W. Burke, G. S. Ginsburg, R. Mills, R. Agans, Primary care physicians' knowledge of and experience with pharmacogenetic testing. Clin. Genet. 82, 388-394 (2012).
137. K. P. Powell, W. A. Cogswell, C. A. Christianson, G. Dave, A. Verma, S. Eubanks, V. C. Henrich, Primary care physicians' awareness, experience and opinions of direct-to-consumer genetic testing. J. Genet. Couns. 21, 113-126 (2012).
138. E. J. Houwink, S. J. van Luijk, L. Henneman, C. van der Vleuten, G. Jan Dinant, M. C. Cornel, Genetic educational needs and the role of genetics in primary care: A focus group study with multiple perspectives. BMC Fam. Pract. 12, 5 (2011).
139. U.S. National Institutes of Health, Genetics education and training: Report of the Secretary's Advisory Committee on Genetics, Health, and Society; http://oba.od.nih.gov/oba/ SACGHS/reports/SACGHS-education-report-2011.pdf.
140. National Coalition for Health Professionals Education in Genetics, Core competencies for all health professionals; http://www.nchpeg.org/index.php? option=com-content&view= article&id=237&Itemid=84.
141. J. Magee, J. I. Gordon, A. Whelan, Bringing the human genome and the revolution in bioinformatics to the medical school classroom: A case report from Washington University School of Medicine. Acad. Med. 76, 852-855 (2001).
142. B. R. Korf, Integration of genetics into clinical teaching in medical school education. Genet. Med. 4, 33S-38S (2002).
143. C. M. Wiener, P. A. Thomas, E. Goodspeed, D. Valle, D. G. Nichols, "Genes to society" - The logic and process of the new curriculum for the Johns Hopkins University School of Medicine. Acad. Med. 85, 498-506 (2010).
144. S. U. Dhar, R. L. Alford, E. A. Nelson, L. Potocki, Enhancing exposure to genetics and genomics through an innovative medical school curriculum. Genet. Med. 14, 163-167 (2012).
145. The Health Literacy of America's Adults: Results from the 2003 National Assessment of Adult Literacy (National Center for Education Statistics, Washington, DC, 2006).
146. D. H. Lea, K. A. Kaphingst, D. Bowen, I. Lipkus, D. W. Hadley, Communicating genetic and genomic information: Health literacy and numeracy considerations. Public Health Genomics 14, 279-289 (2011).
147. G. S. Ginsburg, J. J. McCarthy, Personalized medicine: Revolutionizing drug discovery and patient care. Trends Biotechnol. 19, 491-496 (2001).
148. D. Wu, A. Sherwood, J. R. Fromm, S. S. Winter, K. P. Dunsmore, M. L. Loh, H. A. Greisman, D. E. Sabath, B. L. Wood, H. Robins, High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci. Transl. Med. 4, 134ra63 (2012).
149. A. C. Logan, H. Gao, C. Wang, B. Sahaf, C. D. Jones, E. L. Marshall, I. Buño, R. Armstrong, A. Z. Fire, K. I. Weinberg, M. Mindrinos, J. L. Zehnder, S. D. Boyd, W. Xiao, R. W. Davis, D. B. Miklos, High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. Proc. Natl. Acad. Sci. U.S.A. 108, 21194-21199 (2011).
150. N. Jiang, J. He, J. A. Weinstein, L. Penland, S. Sasaki, X. S. He, C. L. Dekker, N. Y. Zheng, M. Huang, M. Sullivan, P. C. Wilson, H. B. Greenberg, M. M. Davis, D. S. Fisher, S. R. Quake, Lineage structure of the human antibody repertoire in response to influenza vaccination. Sci. Transl. Med. 5, 171ra19 (2013).
151. T. M. Snyder, K. K. Khush, H. A. Valantine, S. R. Quake, Universal noninvasive detection of solid organ transplant rejection. Proc. Natl. Acad. Sci. U.S.A. 108, 6229-6234 (2011).
152. E. E. Schadt, S. Turner, A. Kasarskis, A window into third-generation sequencing. Hum. Mol. Genet. 19, R227-R240 (2010).
153. International Cancer Genome Consortium; T. J. Hudson, W. Anderson, A. Artez, A. D. Barker, C. Bell, R. R. Bernabé, M. K. Bhan, F. Calvo, I. Eerola, D. S. Gerhard, A. Guttmacher, M. Guyer, F. M. Hemsley, J. L. Jennings, D. Kerr, P. Klatt, P. Kolar, J. Kusada, D. P. Lane, F. Laplace, L. Youyong, G. Nettekoven, B. Ozenberger, J. Peterson, T. S. Rao, J. Remacle, A. J. Schafer, T. Shibata, M. R. Stratton, J. G. Vockley, K. Watanabe, H. Yang, M. M. Yuen, B. M. Knoppers, M. Bobrow, A. Cambon-Thomsen, L. G. Dressler, S. O. Dyke, Y. Joly, K. Kato, K. L. Kennedy, P. Nicolás, M. J. Parker, E. Rial-Sebbag, C. M. Romeo-Casabona, K. M. Shaw, S. Wallace, G. L. Wiesner, N. Zeps, P. Lichter, A. V. Biankin, C. Chabannon, L. Chin, B. Clément, E. de Alava, F. Degos, M. L. Ferguson, P. Geary, D. N. Hayes, T. J. Hudson, A. L. Johns, A. Kasprzyk, H. Nakagawa, R. Penny, M. A. Piris, R. Sarin, A. Scarpa, T. Shibata, M. van de Vijver, P. A. Futreal, H. Aburatani, M. Bayés, D. D. Botwell, P. J. Campbell, X. Estivill, D. S. Gerhard, S. M. Grimmond, I. Gut, M. Hirst, C. López-Otín, P. Majumder, M. Marra, J. D. McPherson, H. Nakagawa, Z. Ning, X. S. Puente, Y. Ruan, T. Shibata, M. R. Stratton,H.G. Stunnenberg, H. Swerdlow, V. E. Velculescu, R. K. Wilson, H. H. Xue, L. Yang, P. T. Spellman, G. D. Bader, P. C. Boutros, P. J. Campbell, P. Flicek, G. Getz, R. Guigó, G. Guo, D. Haussler, S. Heath, T. J. Hubbard, T. Jiang, S. M. Jones, Q. Li, N. López-Bigas, R. Luo, L. Muthuswamy, B. F. Ouellette, J. V. Pearson, X. S. Puente, V. Quesada, B. J. Raphael, C. Sander, T. Shibata, T. P. Speed, L. D. Stein, J. M. Stuart, J.W. Teague, Y. Totoki, T. Tsunoda,A. Valencia,D.A. Wheeler, H. Wu, S. Zhao, G. Zhou, L. D. Stein, R.Guigó, T. J. Hubbard, Y. Joly, S. M. Jones, A. Kasprzyk, M. Lathrop, N. López-Bigas, B. F. Ouellette, P. T. Spellman, J.W. Teague, G. Thomas, A. Valencia, T. Yoshida, K. L. Kennedy,M. Axton, S.O. Dyke, P. A. Futreal, D. S. Gerhard, C. Gunter, M. Guyer, T. J. Hudson, J. D. McPherson, L. J. Miller, B. Ozenberger, K. M. Shaw, A. Kasprzyk, L. D. Stein, J. Zhang, S. A. Haider, J. Wang, C. K. Yung, A. Cros, Y. Liang, S. Gnaneshan, J. Guberman, J. Hsu, M. Bobrow, D. R. Chalmers, K. W. Hasel, Y. Joly, T. S. Kaan, K. L. Kennedy, B. M. Knoppers, W. W. Lowrance, T. Masui, P. Nicolás, E. Rial-Sebbag, L. L. Rodriguez, C. Vergely, T. Yoshida, S. M. Grimmond, A. V. Biankin, D. D. Bowtell, N. Cloonan, A. deFazio, J. R. Eshleman, D. Etemadmoghadam, B. B. Gardiner, J. G. Kench, A. Scarpa, R. L. Sutherland, M. A. Tempero, N. J. Waddell, P. J. Wilson, J. D. McPherson, S. Gallinger, M. S. Tsao, P. A. Shaw, G. M. Petersen, D. Mukhopadhyay, L. Chin, R. A. DePinho, S. Thayer, L. Muthuswamy, K. Shazand, T. Beck, M. Sam, L. Timms, V. Ballin, Y. Lu, J. Ji, X. Zhang, F. Chen, X. Hu, G. Zhou, Q. Yang, G. Tian, L. Zhang, X. Xing, X. Li, Z. Zhu, Y. Yu, J. Yu, H. Yang, M. Lathrop, J. Tost, P. Brennan, I. Holcatova, D. Zaridze, A. Brazma, L. Egevard, E. Prokhortchouk, R. E. Banks, M. Uhlén, A. Cambon-Thomsen, J. Viksna, F. Ponten, K. Skryabin, M. R. Stratton, P. A. Futreal, E. Birney, A. Borg, A. L. Børresen-Dale, C. Caldas, J. A. Foekens, S. Martin, J. S. Reis-Filho, A. L. Richardson, C. Sotiriou, H. G. Stunnenberg, G. Thoms, M. van de Vijver, L. van't Veer, F. Calvo, D. Birnbaum, H. Blanche, P. Boucher, S. Boyault, C. Chabannon, I. Gut, J. D. Masson-Jacquemier, M. Lathrop, I. Pauporté, X. Pivot, A. Vincent-Salomon, E. Tabone, C. Theillet, G. Thomas, J. Tost, I. Treilleux, F. Calvo, P. Bioulac-Sage, B. Clément, T. Decaens, F. Degos, D. Franco, I. Gut, M. Gut, S. Heath, M. Lathrop, D. Samuel, G. Thomas, J. Zucman-Rossi, P. Lichter, R. Eils, B. Brors, J.O. Korbel, A. Korshunov, P. Landgraf, H. Lehrach, S. Pfister, B. Radlwimmer, G. Reifenberger, M. D. Taylor, C. von Kalle, P. P. Majumder, R. Sarin, T. S. Rao, M. K. Bhan, A. Scarpa, P. Pederzoli, R. A. Lawlor, M. Delledonne, A. Bardelli, A. V. Biankin, S. M. Grimmond, T. Gress, D. Klimstra, G. Zamboni, T. Shibata, Y. Nakamura, H. Nakagawa, J. Kusada, T. Tsunoda, S. Miyano, H. Aburatani, K. Kato, A. Fujimoto, T. Yoshida, E. Campo, C. López-Otín, X. Estivill, R. Guigó, S. de Sanjoséé, M. A. Piris, E. Montserrat, M. González- Díaz, X. S. Puente, P. Jares, A. Valencia, H. Himmelbauer, V. Quesada, S. Bea, M. R. Stratton, P. A. Futreal, P. J. Campbell, A. Vincent-Salomon, A. L. Richardson, J. S. Reis-Filho, M. van de Vijver, G. International network of cancer genome projects. Nature 464, 993-998 (2010).
154. N. Eriksson, J. M. Macpherson, J. Y. Tung, L. S. Hon, B. Naughton, S. Saxonov, L. Avey, A. Wojcicki, I. Pe'er, J. Mountain, Web-based, participant-driven studies yield novel genetic associations for common traits. PLoS Genet. 6, e1000993 (2010).
155. A. C. Janssens, P. Kraft, Research conducted using data obtained through online communities: Ethical implications of methodological limitations. PLoS Med. 9, e1001328 (2012).
156. R. R. Kalf, R. Bakker, A. C. Janssens, Predictive ability of direct-to-consumer pharmacogenetic testing: When is lack of evidence really lack of evidence? Pharmacogenomics 14, 341-344 (2013).
157. World Health Organization, International statistical classification of diseases and related health problems 10th revision; http://apps.who.int/ classifications/icd10/browse/2010/en.
158. E. Campo, S. H. Swerdlow, N. L. Harris, S. Pileri, H. Stein, E. S. Jaffe, The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications. Blood 117, 5019-5032 (2011).
159. J. W. Vardiman, J. Thiele, D. A. Arber, R. D. Brunning, M. J. Borowitz, A. Porwit, N. L. Harris, M. M. Le Beau, E. Hellström-Lindberg, A. Tefferi, C. D. Bloomfield, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 114, 937-951 (2009).
160. W. D. Travis, E. Brambilla, M. Noguchi, A. G. Nicholson, K. R. Geisinger, Y. Yatabe, D. G. Beer, C. A. Powell, G. J. Riely, P. E. VanSchil, K.Garg, J.H. Austin, H.Asamura, V.W. Rusch, F. R.Hirsch, G. Scagliotti, T. Mitsudomi, R. M. Huber, Y. Ishikawa, J. Jett, M. Sanchez-Cespedes, J. P. Sculier, T. Takahashi, M. Tsuboi, J. Vansteenkiste, I. Wistuba, P. C. Yang, D. Aberle, C. Brambilla, D. Flieder, W. Franklin, A. Gazdar, M. Gould, P. Hasleton, D. Henderson, B. Johnson, D. Johnson, K. Kerr, K. Kuriyama, J. S. Lee, V. A. Miller, I. Petersen, V. Roggli, R. Rosell, N. Saijo, E. Thunnissen, M. Tsao, D. Yankelewitz, International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol. 6, 244-285 (2011).
161. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease (National Academies Press, Washington, DC, 2011).
162. World Economic Forum, Global agenda council on personalized & precision medicine 2012-2013; http://www.weforum.org/content/global-agenda- council-personalizedprecision- medicine-2012.
163. A. N. Kho, J. A. Pacheco, P. L. Peissig, L. Rasmussen, K. M. Newton, N. Weston, P. K. Crane, J. Pathak, C. G. Chute, S. J. Bielinski, I. J. Kullo, R. Li, T. A. Manolio, R. L. Chisholm, J. C. Denny, Electronic medical records for genetic research: Results of the eMERGE consortium. Sci. Transl. Med. 3, 79re1 (2011).
164. B. Carlson, Vanderbilt pioneers bedside genetics. Biotechnol. Healthc. 9, 31-32 (2012).
165. E. Dolgin, Preemptive genotyping trialed to prevent adverse drug reactions. Nat. Med. 17, 1323 (2011).
166. V. Gubala, L. F. Harris, A. J. Ricco, M. X. Tan, D. E. Williams, Point of care diagnostics: Status and future. Anal. Chem. 84, 487-515 (2012).
167. E. J. Topol, The Creative Destruction of Medicine: How the Digital Revolution Will Create Better Health Care (Basic Books, New York, 2012).
168. R. Chen, G. I. Mias, J. Li-Pook-Than, L. Jiang, H. Y. Lam, R. Chen, E. Miriami, K. J. Karczewski, M. Hariharan, F. E. Dewey, Y. Cheng, M. J. Clark, H. Im, L. Habegger, S. Balasubramanian, M. O'Huallachain, J. T. Dudley, S. Hillenmeyer, R. Haraksingh, D. Sharon, G. Euskirchen, P. Lacroute, K. Bettinger, A. P. Boyle, M. Kasowski, F. Grubert, S. Seki, M. Garcia, M. Whirl-Carrillo, M. Gallardo, M. A. Blasco, P. L. Greenberg, P. Snyder, T. E. Klein, R. B. Altman, A. J. Butte, E. A. Ashley, M. Gerstein, K. C. Nadeau, H. Tang, M. Snyder, Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 148, 1293-1307 (2012).
169. A. K. Zaas, M. Chen, J. Varkey, T. Veldman, A. O. Hero III, J. Lucas, Y. Huang, R. Turner, A. Gilbert, R. Lambkin-Williams, N. C. Øien, B. Nicholson, S. Kingsmore, L. Carin, C. W. Woods, G. S. Ginsburg, Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe 6, 207-217 (2009).